

June 14, 2019

To whom it may concern:

|   |  |
|---|--|
| Company Name<br>Corporate<br>Representative | TOHO HOLDINGS CO., LTD.<br>Norio Hamada, Chairman of the Board<br>and Representative Director, Chief<br>Executive Officer (CEO)<br>(First Section of Tokyo Stock<br>Exchange Securities Code:8129) |
| Contact:                                    | Makoto Kawamura, Director and<br>General Manager, Public and Investor<br>Relations Department<br>(TEL: 81-3-6838-2803)   |

### Notice Regarding Launch of 1 Ingredient / 4 Products of Generic Drugs for KYOSOMIRAI PHARMA

TOHO HOLDINGS CO., LTD. (Headquarters: Tokyo; Chairman of the Board and Representative Director, Chief Executive Officer (CEO): Norio Hamada) is pleased to announce that KYOSOMIRAI PHARMA CO., LTD. (Headquarters: Tokyo; President and Representative Director: Atsushi Udoh), the wholly-owned subsidiary involved in pharmaceuticals manufacture and sales business, has launched 1 ingredient / 4 products of generic drugs today on June 14, 2019 as below.

#### New products list

| Class   | Product Name                            | Original Brand Name     |
|---|---|-------------------------|
| Selective $\alpha$ 1A blocker<br>Improving agent for urination<br>disorders associated with benign<br>prostatic hyperplasia | Silodosin Tablets<br>2mg / 4mg “KMP”    | URIEF Tab. 2mg / 4mg    |
|   | Silodosin OD Tablets<br>2mg / 4mg “KMP” | URIEF OD Tab. 2mg / 4mg |